Pfizer (NYSE:PFE) Shares Up 0.1%

Pfizer Inc. (NYSE:PFE) shares were up 0.1% during trading on Friday . The company traded as high as $28.99 and last traded at $28.72. Approximately 5,715,090 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 42,192,773 shares. The stock had previously closed at $28.69.

Analyst Ratings Changes

Several research analysts have weighed in on the company. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley boosted their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Finally, Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $35.86.

Pfizer Trading Up 0.0 %

The firm has a fifty day moving average price of $27.26 and a 200 day moving average price of $27.98. The company has a market cap of $162.63 billion, a price-to-earnings ratio of -478.59, a P/E/G ratio of 1.16 and a beta of 0.63. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s revenue was down 19.5% on a year-over-year basis. During the same period last year, the business posted $1.23 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.85%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Hedge Funds Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Lincoln National Corp lifted its holdings in Pfizer by 12.9% during the 3rd quarter. Lincoln National Corp now owns 140,979 shares of the biopharmaceutical company’s stock worth $4,676,000 after purchasing an additional 16,110 shares during the last quarter. Nicholas Hoffman & Company LLC. lifted its holdings in shares of Pfizer by 3.2% during the third quarter. Nicholas Hoffman & Company LLC. now owns 32,148 shares of the biopharmaceutical company’s stock worth $1,066,000 after buying an additional 998 shares in the last quarter. Meyer Handelman Co. boosted its position in shares of Pfizer by 6.3% in the third quarter. Meyer Handelman Co. now owns 1,475,753 shares of the biopharmaceutical company’s stock valued at $48,951,000 after acquiring an additional 87,840 shares during the period. Assenagon Asset Management S.A. increased its position in Pfizer by 36.0% during the third quarter. Assenagon Asset Management S.A. now owns 4,182,166 shares of the biopharmaceutical company’s stock worth $138,722,000 after acquiring an additional 1,107,971 shares during the period. Finally, Wrapmanager Inc. raised its stake in Pfizer by 3.1% in the 3rd quarter. Wrapmanager Inc. now owns 26,120 shares of the biopharmaceutical company’s stock worth $866,000 after purchasing an additional 779 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.